Comparison of chemiluminescent microparticle immunoassay with electrochemiluminescence immunoassay for carcinoembryonic antigen

Nafija Serdarevic1,2*, Jasmina Smajic1

1Institute for Clinical Biochemistry and Immunology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina, 2Faculty of Health Sciences, Bolnicka 25, Sarajevo, Bosnia and Herzegovina

ABSTRACT

Introduction: Carcinoembryonic antigen (CEA) is used for monitoring of disease progression and treatment response in cancer patients. The aim was to compare the performance of chemiluminescent microparticle immunoassay with electrochemiluminescence immunoassay for CEA.

Methods: A total of 115 samples were collected during routine diagnostic, prognostic, and therapy monitoring procedures in patients with colorectal and pancreatic cancer. We used Architect i2000SR and Cobas E601 for CEA analysis in sera samples.

Results: The correlation coefficient of 0.984 (95% confidence interval [CI]: 0.972–0.991) for results obtained on both platforms was observed for CEA ≤10 ng/mL group. Moreover, intercept of 0.9027 (95% CI: 0.705–1.099) and slope 0.8076 (95% CI: 0.765–0.8498) (p < 0.0001) were observed in this group. In CEA >10 ng/mL group, we observed slope = 1.1986 (95% CI: 1.1474–1.2498) (p < 0.0001), intercept = –11.69 (–17.53–3.84), and correlation coefficient = 0.985 (95% CI: 0.976–0.9914). Mean differences between assays in group ≤10 ng/mL and >10 ng/mL were 0.2066 (95% CI: 0.0019–0.4113) and –2.66 (95% CI: −10.10–4.76) ng/mL, respectively.

Conclusion: Although there were differences, based on 20 days’ precision tests, overall results showed a good analytical performance and correlation between CEA assays on Architect i2000SR and Cobas E601 platforms. Reference intervals appropriate for the method of CEA measurement should be used. The standardization and harmonization of serum CEA concentration assays are needed.

Key words: Carcinoembryonic antigen; chemiluminescent microparticle immunoassay; electrochemiluminescence immunoassay; immunoassays

INTRODUCTION

Cancer can be detected and monitored using biologic tumor markers. Tumor markers are produced either directly by the tumor or as an effect of the tumor on healthy tissue. Ideally, a tumor marker would be tumor specific, absent in healthy individuals, and...
readily detectable in body fluids. Unfortunately, all of
the currently available tumor markers do not fit this
ideal model (1). Carcinoembryonic antigen (CEA)
is a large glycoprotein with molecular weight of
approximately 200 kD. CEA is the most widely used
tumor marker for colorectal cancer and is also fre-
fquently elevated in a lung, breast, and gastrointestinal
tumors (2). Most studies have adopted a CEA cutoff
point <3.0 ng/mL for healthy non-smokers, between
3.0 and 5.0 ng/mL for healthy smokers, gray zone for
levels between 5.0 and 10.0 ng/mL, cancer for levels
between 10.0 and 20.0 ng/mL, and metastasis for lev-
eels >20.0 ng/mL (3,4). In colon cancer, CEA is used
for prognosis, postsurgery surveillance, and chemo-
therapy response monitoring (5). CEA determination
is available on numerous automated analysis plat-
forms. Due to the high heterogeneity of polyclonal
antibodies for CEA, it is advised that the same assay
is used for serial monitoring (6). In competitive
chemiluminescence assay, patient antigen and labeled
antigen compete for the limited number of antibody
binding sites. Free and bound reagent antigen must be
separated before the label is measured. The label may
be measured on either free or bound reagent antigen
and is related to the amount of patient antigen in
the sample. The chemiluminescence is produced by
compounds such as luminol and acridinium esters
that can produce light energy by chemical reaction.
On separation of free and bound reagent antigen,
an enzyme (usually firefly luciferase) is used to pro-
duce chemiluminescence, which is measured with a
luminometer (7). Harmonization of results among
different clinical laboratory measurement procedures
may be achieved by calibration traceability (8). The
International Organization for Standardization stan-
dard 17511: 2003 published a material which pro-
vides the framework for calibration traceability in
laboratory medicine (9). Automated immunoassays
may have different methodology principle, antigens,
epitopes, and reagents. Thus, CEA concentration
obtained by different automated analyzers is differ-
ent, and harmonization of CEA concentration results
obtained using different immunoassays has not yet
been achieved (10).

The aim was to compare the performance of che-
miluminescent microparticle immunoassay (CMIA)
with electrochemiluminescence immunoassay
(ECLIA) for CEA.

METHODS

Test procedure

In our study, assays were performed according to
the manufacturers’ instructions. The CMIA is a non-competitive sandwich assay technology
used to measure analytes. The amount of signal is
directly proportional to the amount of analyte pre-
sent in the sample. Architect (Abbott) CEA assay is
a two-step immunoassay to determine the presence
of CEA in human serum using CMIA technology.
The reference range for CEA in Architect CMIA
is 0–3 ng/mL. ARCHITECT (CMIA) detection
limit is 0.5 ng/mL at the 95% level of confidence
and measuring range 0.5–1500 ng/mL. The ECLIA
is based on the use of a ruthenium complex and
tripropylamine. The Cobas E601 (Roche, Basel,
Switzerland) detection limit is 0.2 ng/mL and
measuring range is 0.20–1000 ng/mL. The refer-
ce range of CEA in Cobas E601 ECLIA technol-
ogy for healthy non-smokers is 0–3.8 ng/mL and
for healthy smokers is 0–5.0 ng/mL (9). We per-
formed measurements of CEA with single reagent
lot and single calibrator lot; CEA calibrator lot;
Architect i2000SR (Abbott, cat. no. 61019FN00),
and Cobas E601 (Roche Diagnostics; CEA cat.
o. 2699370). The Abbott (Architect i2000SR)
calibrator contains internal standard manufact-
ured using highly purified material and Roche
(Cobas E601) calibrator contains 1st International
Reference Pricing World Health Organization re-
ference standard 73/601.

Patients

This study was conducted from July 2017 to April
2018 and included 115 patients (70 male and
45 female), between 65 and 85 years old, hospi-
 talized at the Oncology Clinic, University Clinical
Center Sarajevo. The patients’ samples were col-
lected in serum separator Vacutainer test tubes
(Becton Dickinson, Rutherford, NJ, U.S.) in a
volume of 3.5 mL. Serum samples were obtained
by centrifugation at 3000 rpm using Centrifuge
SIGMA 3-16P (SIGMA Laborzentrifugen GmbH,
Osterode am Harz, Germany). After centrifug-
ing, serum concentration of CEA was deter-
mined. The study protocol followed the ethical
guidelines given in the Declaration of Helsinki,
and informed consent was obtained from all participants. Patients’ samples were collected and assigned to four groups according to the Architect CEA values: CEA <2.5 ng/mL (10 samples), 2.5–5.0 ng/mL (20 samples), 5.0–10 ng/mL (20 samples), and ≥10.0 ng/mL (65 samples).

Patients’ inclusion and exclusion criteria
In our study, serum concentration of CEA was determined as a part of the diagnosis, prognosis, and therapy monitoring of colorectal and pancreatic cancer. The patients with renal failure and fulminant hepatitis have falsely increased CEA values. Furthermore, patients with hypothyroidism may also have elevated levels of CEA. The levels of CEA may be raised in some non-neoplastic conditions such as ulcerative colitis, pancreatitis, cirrhosis, chronic obstructive pulmonary disease, and Crohn’s disease. Therefore, patients with the conditions mentioned above were excluded from the study. Since hemolysis, icterus, and lipemia can affect tumor marker immunoassay measurements, such samples were excluded from the study as well (11).

Serum samples
Serum samples were collected, separated from the clot, and stored at 2–8°C for up to 24 h. If measurements were not performed within 24 h, the samples were stored at −20°C. To prevent thawing effects, each sample was aliquoted in two aliquots, i.e., one aliquot per assay. Aliquots were stored in the same manner as mentioned, to avoid variation in storage conditions (12).

Imprecision
Quality control was performed using corresponding commercial control samples with low, medium, and high CEA concentrations for Architect i2000SR and Cobas E601 provided by the manufacturers. We analyzed precision (intra-assay variation) by measuring CEA using control samples for ARCHITECT i2000SR and Cobas E601 (n = 20). The reproducibility (interassay variation) was tested with the same control samples once a day over 10 consecutive days. Recovery studies were performed in both the systems (Architect and Cobas) for CEA.

Statistical analysis
Statistical analysis was performed using MedCalc software and SPSS version 16.0 software (SPSS Inc., Chicago, USA). Data were analyzed using descriptive statistic average values (x), standard deviation (SDs), Pearson correlation coefficient (r), and equations of linear regression. The method of comparison was Passing and Bablok. The analysis was performed using Bland–Altman plot to test the limits of agreement. The difference between the samples was analyzed using paired t-test, with the statistical significance level set at p < 0.001.

RESULTS

Quality control testing
Three types of controls (n = 20) with low, medium, and high levels of CEA were used for quality control testing. The results of quality control testing for the two immunoassays are shown in Table 1.

Accuracy testing
We compared CEA concentrations measured in 115 by Architect i2000SR (CMIA) and Cobas E601 (ECLIA) technology. CEA assays differ by a constant factor as shown by the intercept = 0.9027 (95% confidence interval [CI]: 0.705–1.099). The proportional difference was observed, shown by the slope = 0.8076 (95% CI: 0.765–0.8498) (p < 0.0001). The Cusum test of linearity was p = 0.26. The regression equation for CEA ≤10 ng/mL group was y = 0.9027 + 0.81776x. The correlation coefficient of 0.984 (95% CI: 0.972–0.991) was observed for the same group (Figure 1). In the CEA >10 ng/mL group, we obtained following results following regression analysis statistics: Slope = 1.1986 (95% CI: 1.1474–1.2498) (p < 0.0001); intercept = −11.69 (95% CI: −17.53–−5.84); and correlation coefficient = 0.985 (95% CI: 0.976–0.9914). Furthermore, regression equation within this group was y = 3.617807 + 1.04390x in Figure 2. The average mean values for CEA ≤10 ng/mL group measured by Abbott and Roche assay were 3.11 ng/mL and 3.82 ng/mL, respectively (95% CI: 2.76–4.46 ng/mL and 3.12–4.52 ng/mL, respectively). Method comparison analysis using Bland–Altman plot to test limits of agreement (−1.96s→+1.96) between Abbott and Roche assay
### TABLE 1. Quality control testing

<table>
<thead>
<tr>
<th>Concentration spiked (ng/mL)</th>
<th>Concentration found intraassay (Mean±SD, n=20) (ng/mL)</th>
<th>Precision intraassay (%)</th>
<th>Concentration found interassay (Mean±SD, n=20) (ng/mL)</th>
<th>Reproducibility (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Architect CEA assay CMIA technology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.30–6.70</td>
<td>4.8±0.16</td>
<td>3.5</td>
<td>4.5±0.16</td>
<td>3.7</td>
</tr>
<tr>
<td>13.0–27.0</td>
<td>19.9±0.55</td>
<td>2.8</td>
<td>20.1±0.60</td>
<td>3.0</td>
</tr>
<tr>
<td>65.0–135.0</td>
<td>99.12±2.08</td>
<td>2.1</td>
<td>97.3±2.62</td>
<td>2.7</td>
</tr>
<tr>
<td>Cobas CEA assay ECLIA technology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.36–6.40</td>
<td>3.79±0.09</td>
<td>2.5</td>
<td>3.92±0.14</td>
<td>3.70</td>
</tr>
<tr>
<td>35.6–54.5</td>
<td>37.58±0.63</td>
<td>1.7</td>
<td>39.4±1.22</td>
<td>3.10</td>
</tr>
</tbody>
</table>

SD: Standard deviation, CEA: Carcinoembryonic antigen, CMIA: Chemiluminescent microparticle immunoassay, ECLIA: Electrochemiluminescence immunoassay

**FIGURE 1.** Comparison of carcinoembryonic antigen (CEA) concentration in CEA ≤10 ng/mL group using Architect i2000SR immunoassay analyzer and Cobas E601 analyzer ($r = 0.972–0.991$).

**FIGURE 2.** Comparison of carcinoembryonic antigen (CEA) concentration in CEA >10 ng/mL group using Architect i2000SR immunoassay analyzer and Cobas E601 analyzer ($r = 0.976–0.9914$).
for CEA ≤10 ng/mL - group showed mean difference of 0.2066 (95% CI: 0.0019–0.4113) ng/mL (Figure 3). In CEA ≥10 ng/mL group, mean difference was −2.66 (95% CI: −10.10–4.76) ng/mL (Figure 4). The results of our study have shown that average mean values of CEA in CEA ≥10 ng/mL group measured by Abbott and Roche assay were 42.76 ng/mL and 45.43 ng/mL, respectively (95% CI: 10.95–71.59 ng/mL and 19.26–74.56 ng/mL, respectively). The concordance between the results was high in lower and higher CEA concentrations.

DISCUSSION
In our study, we compared two widely used automated CEA assays. 80% of healthy subjects have CEA concentration <3 ng/mL (13). In Architect CMIA and Cobas ECLIA based on the Levey-Jennings quality control test report, was <2 SD. The results of Levey-Jennings report confirm very good quality control. In our study, CMIA technology has precision 2.1–3.5% and reproducibility 2.7–3.7%. The other method technology ECLIA had the precision of 1.7–2.5% and reproducibility of 3.1–3.7% (Table 1). The investigation of Hendriks et al. (14)
has shown that CMIA technology had the precision of 2.5–3.5% and ECLIA had the precision of 2.5–5.1%. In our study, we obtained a high concordance of results in CEA ≤0–10 ng/mL group between Architect and Cobas. We have shown regression analysis slope = 0.8076 (95% CI: 0.765–0.8498) and intercept = 0.9027 (95% CI: 0.705–1.099) with high correlation coefficient \( r = 0.972–0.991 \) and \( p < 0.0001 \) as shown in Figure 1. The method comparison of the assays for the CEA >10 ng/mL resulted in the following regression analysis statistic: Slope = 1.1986 (95% CI: 1.147–1.2498) (\( p < 0.0001 \)), intercept = –11.69 (95% CI: –17.53– –5.84), and the correlation coefficient = 0.985 (95% CI: 0.976–0.9914), and \( p < 0.0001 \) was observed in this group, as shown in Figure 2. Previous studies have shown a good correlation between Architect (Abbott) and Elecsys E170 (Roche) \( (r = 0.994) \) (12). The Cusum test for linearity for the CEA ≤10 ng/mL group obtained \( p = 0.74 \) and for the CEA >10 ng/mL group obtained \( p = 0.15 \). The study of the comparison of CEA immunoassays Architect i2000SR (Abbott) and Elecsys E170 (Roche) has shown Cusum test for linearity \( p\)-value of 0.33 for CEA <100 ng/mL (15). The results of our study showed that three patients had CEA serum values >5 ng/mL measured by the Cobas E601, while the values were within reference range measured by Architect i2000SR. Four of patients had CEA serum values >10 ng/mL measured by Cobas E601 while values were <10.0 ng/mL in a gray zone when measured by Architect i2000SR. The CEA cut-off point is below 3.0 ng/mL, grey zone between 5.0 and 10.0 ng/mL and cancer between 10.0 and 20.0 ng/mL,\( (3,4) \) The Cobas ECLI A limit of detection for CEA was 0.2 ng/mL and for Architect CMIA was 0.5 ng/mL. The difference in the limit of detection could be one of the explanations of result differences in CEA determination using ECLI A and CMIA technology. We have shown that even though CEA values in Architect i2000SR and Cobas E601 assays highly correlate in all CEA concentration intervals <10 ng/mL and ≥10 ng/mL, they are not the same. The Architect i2000SR assay overall provided results 5.8–6.2% lower than the Cobas E601 results. Furthermore, at a critical concentration of 10 ng/mL, a 6.2% relative difference was observed, with higher values being observed in Cobas E601. The differences between assay measurements are of sufficient magnitude that CEA results are not interchangeable. The detection method for the architect i2000SR is chemiluminescence and for Cobas E601 is electrochemiluminescence. There is no reason to assume that one is more accurate than the other; however, users of the assays must be aware of these differences. The investigation from Park et al. (15) has shown the mean difference between the CMIA and ECLI A technologies from 1.2% to 2.2% where Architect had lower results than the Cobas E601. The Architect had a lower concentration of CEA in comparison with the previous method of Roche (Elecsys E170 and Elecsys 2010). The differences might be explained due to the diluent matrix effects or interactions between components from blood collection tubes and blood samples (14,15). It is empirically known that repetitive sampling using different methods may show significant variations in results; this fact, if not taken into account, this could lead to inappropriate clinical decisions (16–20). The results of our study showed that the mean difference in CEA concentration in group ≤10 ng/mL was 0.2066 (95% CI: 0.0019–0.4113), as shown in Figure 3. Mean differences of CEA concentration in CEA >10 ng/mL group was –2.66 (95% CI: –10.10–4.76) ng/mL, as shown in Figure 4. Similar comparison method results were reported in a study by Sturgeon et al. (12). The differences in reference range for each immunoassay and instrument-specific calibration and working standard could result in inconsistent CEA results between assays. Precautions should be taken since CEA concentration from automated immunoassays is not comparable (10,15). The main limitation of our study is a small number of samples and the non-Gaussian distribution of CEA concentration present in the whole study population.

CONCLUSION

The results of our study showed a good analytical performance and correlation of CEA assays based on 20 days of precision tests on Architect i2000SR and Cobas E601 platforms. Nevertheless, the CEA analysis for each patient should be performed with the same reagents on the same analyzer despite their comparability. One of the problems is the long-term
monitoring because patients can change the hospital or the laboratory can introduce a new method of evaluation of tumor markers. Ideally, the results obtained by different methods should be fully comparable. In the future, it will be necessary to define a new baseline concentration of CEA for monitoring each patient. In addition, it is necessary to perform standardization and harmonization of different CEA immunoassays in the future.

REFERENCES